Literature DB >> 26020032

Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Chiun Hsu1, Bang-Bin Chen2, Chien-Hung Chen3, Ming-Chih Ho4, Jason Chia-Hsien Cheng1, Norihiro Kokudo5, Takamichi Murakami6, Winnie Yeo7, Jinsil Seong8, Ji-Dong Jia9, Kwan-Hyub Han10, Ann-Lii Cheng11.   

Abstract

A key mission of the Asia-Pacific Primary Liver Cancer Expert (APPLE) Association is to ensure a coherent view for management of hepatocellular carcinoma (HCC) and to advance new treatment for this difficult disease. At the 5th APPLE meeting, held in July 2014 in Taipei, Taiwan, an APPLE consensus development program was established to facilitate discussion among experts in the Asia-Pacific region on pertinent issues for HCC management, including (1) surgery for intermediate/advanced-stage disease, (2) prevention of HCC recurrence after curative treatment, (3) optimizing imaging diagnosis, (4) radiotherapy: current practice and future clinical trials, and (5) the role of cytotoxic chemotherapy. A pre-congress questionnaire was undertaken with the consensus development committee members to help understand the current practice patterns for HCC in the Asia-Pacific region and to identify issues relating to optimal patient care and further clinical trials for which consensus needs to be developed. In this report, the results of the questionnaire are presented, and the pertinent issues identified by each consensus group for further discussion and consensus development are summarized.

Entities:  

Keywords:  Chemotherapy; Hepatocellular carcinoma; Imaging; Radiotherapy; Surgery

Year:  2015        PMID: 26020032      PMCID: PMC4439776          DOI: 10.1159/000367732

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  17 in total

Review 1.  Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria?

Authors:  Pierce Kah-Hoe Chow
Journal:  J Gastroenterol Hepatol       Date:  2012-03       Impact factor: 4.029

2.  Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.

Authors:  Robin K Kelley
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

3.  Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.

Authors:  Kwang-Hyub Han; Masatochi Kudo; Sheng-Long Ye; Jong Young Choi; Roonni Tung-Ping Poon; Jinsil Seong; Joong-Won Park; Takafumi Ichida; Jin Wook Chung; Pierce Chow; Ann-Lii Cheng
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

4.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

Review 5.  Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

6.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Authors:  Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz
Journal:  JAMA       Date:  2010-11-17       Impact factor: 56.272

7.  Systematic evidence-based clinical practice guidelines are ushering in a new stage of standardized management of hepatocellular carcinoma in Japan.

Authors:  Peipei Song; Wei Tang; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  Drug Discov Ther       Date:  2014-04

8.  A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group.

Authors:  Guido Torzilli; Jacques Belghiti; Norihiro Kokudo; Tadatoshi Takayama; Lorenzo Capussotti; Gennaro Nuzzo; Jean-Nicolas Vauthey; Michael A Choti; Eduardo De Santibanes; Matteo Donadon; Emanuela Morenghi; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2013-05       Impact factor: 12.969

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

Review 10.  Diagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current Consensus.

Authors:  Tomoaki Ichikawa; Katsuhiro Sano; Hiroyuki Morisaka
Journal:  Liver Cancer       Date:  2014-05       Impact factor: 11.740

View more
  7 in total

Review 1.  Hepatocellular carcinoma: Where are we?

Authors:  Roberto Mazzanti; Umberto Arena; Renato Tassi
Journal:  World J Exp Med       Date:  2016-02-20

2.  Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials.

Authors:  Hee Chul Park; Jeong Il Yu; Jason Chia-Hsien Cheng; Zhao Chong Zeng; Ji Hong Hong; Michael Lian Chek Wang; Mi Sook Kim; Kwan Hwa Chi; Po-Ching Liang; Rheun-Chuan Lee; Wan-Yee Lau; Kwang Hyub Han; Pierce Kah-Hoe Chow; Jinsil Seong
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

3.  Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.

Authors:  Chung-Wei Su; Ming-Mo Hou; Pei-Wei Huang; Yung-Chih Chou; Bing-Shen Huang; Jeng-Hwei Tseng; Chao-Wei Hsu; Tung-Chieh Chang; Shi-Ming Lin; Chen-Chun Lin
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

Review 4.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

5.  Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Bang-Bin Chen; Takamichi Murakami; Tiffany Ting-Fang Shih; Michiie Sakamoto; Osamu Matsui; Byung-Ihn Choi; Myeong-Jin Kim; Jeong Min Lee; Ren-Jie Yang; Meng-Su Zeng; Ran-Chou Chen; Ja-Der Liang
Journal:  Liver Cancer       Date:  2015-10-15       Impact factor: 11.740

6.  Underutilization of Surgery in Periampullary Cancer Treatment.

Authors:  Christoph W Michalski; Bing Liu; Max Heckler; Susanne Roth; Huihui Sun; Ulrike Heger; Markus W Büchler; Thilo Hackert
Journal:  J Gastrointest Surg       Date:  2018-08-07       Impact factor: 3.452

Review 7.  Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines.

Authors:  Chai Hong Rim; Jinsil Seong
Journal:  Radiat Oncol J       Date:  2016-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.